Neurologic complications of immune checkpoint inhibitors

References

• Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019 Oct 17;381(16):1535–1546.
   PubMed Web of Science ®Google Scholar
• Johnson DB, Chandra S, Sosman JA. Immune checkpoint inhibitor toxicity in 2018. Jama. 2018 Oct 23;320(16):1702–1703.
   PubMed Web of Science ®Google Scholar
• Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018 Mar 23;359(6382):1350–1355.
   PubMed Web of Science ®Google Scholar
• Larkin J, Chmielowski B, Lao CD, et al. Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis. Oncologist. 2017 Jun;22(6):709–718.
   PubMed Web of Science ®Google Scholar
• Kao JC, Brickshawana A, Liewluck T. Neuromuscular complications of programmed cell death-1 (PD-1) inhibitors. Curr Neurol Neurosci Rep. 2018 Aug 4;18(10):63.
   PubMed Web of Science ®Google Scholar
• DB J, Manouchehri A, Am H, et al. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunother Cancer. 2019 May 22;7(1):134.
   PubMedGoogle Scholar
• Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018 Sep;8(9):1069–1086.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012 Mar 22;12(4):252–264.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 Aug 19;363(8):711–723.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012 Jun 28;366(26):2455–2465.
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015 Jul 2;373(1):23–34.
   PubMed Web of Science ®Google Scholar
• Nishijima TF, Shachar SS, Nyrop KA, et al. Safety and tolerability of PD-1/PD-L1 Inhibitors compared with chemotherapy in patients with advanced cancer: a meta-analysis. Oncologist. 2017 Apr;22(4):470–479.
   PubMed Web of Science ®Google Scholar
• Luo W, Wang Z, Tian P, et al. Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trials. J Cancer Res Clin Oncol. 2018 Oct;144(10):1851–1859.
   PubMed Web of Science ®Google Scholar
• Weinmann SC, Pisetsky DS. Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors. Rheumatology (Oxford). 2019 Dec 1;58(Supplement_7):vii59–vii67.
   PubMedGoogle Scholar
• June CH, Warshauer JT, Bluestone JA. Is autoimmunity the Achilles’ heel of cancer immunotherapy? Nat Med. 2017 May 5;23(5):540–547.
   PubMed Web of Science ®Google Scholar
• Stucci S, Palmirotta R, Passarelli A, et al. Immune-related adverse events during anticancer immunotherapy: pathogenesis and management. Oncol Lett. 2017 Nov;14(5):5671–5680.
   PubMed Web of Science ®Google Scholar
• Das R, Bar N, Ferreira M, et al. Early B cell changes predict autoimmunity following combination immune checkpoint blockade. J Clin Invest. 2018 Feb 1;128(2):715–720.
   PubMed Web of Science ®Google Scholar
• Elkrief A, Derosa L, Zitvogel L, et al. The intimate relationship between gut microbiota and cancer immunotherapy. Gut Microbes. 2019;10(3):424–428.
   PubMed Web of Science ®Google Scholar
• Dubin K, Callahan MK, Ren B, et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun. 2016 Feb 2;7(7):10391.
   PubMedGoogle Scholar
• De Luca F, Shoenfeld Y. The microbiome in autoimmune diseases. Clin Exp Immunol. 2019 Jan;195(1):74–85.
   PubMed Web of Science ®Google Scholar
• Salam SLavin T, Turan A. Limbic encephalitis following immunotherapy against metastatic malignant melanoma. BMJ Case Rep. 2016 Mar 23;2016. pii: bcr2016215012. doi: 10.1136/bcr-2016-215012.
   Google Scholar
• Vitt JR, Kreple C, Mahmood N, et al. Autoimmune pancerebellitis associated with pembrolizumab therapy. Neurology. 2018 Jul 10;91(2):91–93.
   PubMed Web of Science ®Google Scholar
• Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016 Apr;15(4):391–404.
   PubMed Web of Science ®Google Scholar
• Cohen J, Sotoca J, Gandhi S, et al. Autoimmune encephalitis: a costly condition. Neurology. 2019 Feb 26;92(9):e964–e72.
   PubMed Web of Science ®Google Scholar
• Williams TJ, Benavides DR, Patrice KA, et al. Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol. 2016 Aug 1;73(8):928–933.
   PubMed Web of Science ®Google Scholar
• Graus F, Dalmau J. Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2019 Sep;16(9):535–548.
   PubMed Web of Science ®Google Scholar
• Brown MP, Hissaria P, Hsieh AH, et al. Autoimmune limbic encephalitis with anti-contactin-associated protein-like 2 antibody secondary to pembrolizumab therapy. J Neuroimmunol. 2017 Apr 15;305:16–18.
   PubMed Web of Science ®Google Scholar
• Yshii LM, Hohlfeld R, Liblau RS. Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives. Nat Rev Neurol. 2017 Dec;13(12):755–763.
   PubMed Web of Science ®Google Scholar
• Hajdu T, Juhasz T, Szucs-Somogyi C, et al. NR1 and NR3B composed intranuclear N-methyl-d-aspartate receptor complexes in human melanoma cells. Int J Mol Sci. 2018 Jun 30;19(7):1929.
   PubMed Web of Science ®Google Scholar
• Yshii LM, Gebauer CM, Pignolet B, et al. CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model. Brain. 2016 Nov 1;139(11):2923–2934.
   PubMedGoogle Scholar
• Vogrig A, Fouret M, Joubert B, et al. Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors. Neurol Neuroimmunol Neuroinflamm. 2019 Nov;6(6):e604.
   PubMed Web of Science ®Google Scholar
• A, Gigli GLSegatti S, et al. Epidemiology of paraneoplastic neurological syndromes: a population-based study. J Neurol. 2019 Sep 24;267(1):26–35.
   PubMed Web of Science ®Google Scholar
• Gozzard P, Woodhall M, Chapman C, et al. Paraneoplastic neurologic disorders in small cell lung carcinoma: a prospective study. Neurology. 2015 Jul 21;85(3):235–239.
   PubMed Web of Science ®Google Scholar
• Mailles A, Stahl JP, Bloch KC. Update and new insights in encephalitis. Clin Microbiol Infect. 2017 Sep;23(9):607–613.
   PubMed Web of Science ®Google Scholar
• Burke M, Hardesty M, Downs W. A case of severe encephalitis while on PD-1 immunotherapy for recurrent clear cell ovarian cancer. Gynecol Oncol Rep. 2018 May;24:51–53.
   PubMed Web of Science ®Google Scholar
• Johnson DB, McDonnell WJ, Gonzalez-Ericsson PI, et al. A case report of clonal EBV-like memory CD4(+) T cell activation in fatal checkpoint inhibitor-induced encephalitis. Nat Med. 2019 Aug;25(8):1243–1250.
   PubMed Web of Science ®Google Scholar
• Armangue T, Spatola M, Vlagea A, et al. Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis. Lancet Neurol. 2018 Sep;17(9):760–772.
   PubMed Web of Science ®Google Scholar
• Peeters LM, Vanheusden M, Somers V, et al. Cytotoxic CD4+ T cells drive multiple sclerosis progression. Front Immunol. 2017;8:1160.
   PubMed Web of Science ®Google Scholar
• Takeuchi A, Saito T. CD4 CTL, a cytotoxic subset of CD4(+) T cells, their differentiation and function. Front Immunol. 2017;8:194.
   PubMed Web of Science ®Google Scholar
• Patel AR, Connors S, Wardak Z, et al. Inflammatory reaction secondary to immune checkpoint inhibitor therapy mimicking a post-operative brain abscess. World Neurosurg. 2019 Sep;129:354–358.
   PubMed Web of Science ®Google Scholar
• Bossart S, Thurneysen S, Rushing E, et al. Case report: encephalitis, with brainstem involvement, following checkpoint inhibitor therapy in metastatic melanoma. Oncologist. 2017 Jun;22(6):749–753.
   PubMed Web of Science ®Google Scholar
• Thompson JA, Schneider BJ, Brahmer J, et al. Management of Immunotherapy-related toxicities, version 1.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 Mar 1;17(3):255–289.
   PubMed Web of Science ®Google Scholar
• Quach HT, Robbins CJ, Balko JM, et al. Severe epididymo-orchitis and encephalitis complicating anti-PD-1 therapy. Oncologist. 2019 Jul;24(7):872–876.
   PubMed Web of Science ®Google Scholar
• Galmiche S, Lheure C, Kramkimel N, et al. Encephalitis induced by immune checkpoint inhibitors in metastatic melanoma: a monocentric retrospective study. J Eur Acad Dermatol Venereol. 2019 Jun 20;33(12). DOI:10.1111/jdv.v33.12.
   PubMed Web of Science ®Google Scholar
• Mohn N, Beutel G, Gutzmer R, et al. Neurological immune related adverse events associated with nivolumab, ipilimumab, and pembrolizumab therapy-review of the literature and future outlook. J Clin Med. 2019 Oct 24;8(11):1777.
   PubMed Web of Science ®Google Scholar
• Sato K, Mano T, Iwata A, et al. Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese adverse drug event report database. J Neurooncol. 2019 Oct;145(1):1–9
   PubMedGoogle Scholar
• Astaras C, de Micheli R, Moura B, et al. Neurological adverse events associated with immune checkpoint inhibitors: diagnosis and management. Curr Neurol Neurosci Rep. 2018 Feb 1;18(1):3.
   PubMed Web of Science ®Google Scholar
• Tan MH, Iyengar R, Mizokami-Stout K, et al. Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports. Clin Diabetes Endocrinol. 2019;5(1):1.
   PubMedGoogle Scholar
• Joshi MN, Whitelaw BC, Palomar MT, et al. Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review. Clin Endocrinol (Oxf). 2016 Sep;85(3):331–339.
   PubMed Web of Science ®Google Scholar
• Takamatsu D, Furubayashi N, Negishi T, et al. Relapse of aseptic meningitis induced by ipilimumab and nivolumab therapy for metastatic renal cell carcinoma: a case report. Mol Clin Oncol. 2019 Dec;11(6):590–594.
   PubMed Web of Science ®Google Scholar
• Garcia CR, Jayswal R, Adams V, et al. Multiple sclerosis outcomes after cancer immunotherapy. Clin Transl Oncol. 2019 Oct;21(10):1336–1342.
   PubMed Web of Science ®Google Scholar
• Kumar N, Abboud H. Iatrogenic CNS demyelination in the era of modern biologics. Mult Scler. 2019 Jul;25(8):1079–1085.
   PubMed Web of Science ®Google Scholar
• Zafar Z, Vogler C, Hudali T, et al. Nivolumab-associated acute demyelinating encephalitis: a case report and literature review. Clin Med Res. 2019 Jun;17(1–2):29–33.
   PubMed Web of Science ®Google Scholar
• Maurice C, Schneider R, Kiehl TR, et al. Subacute CNS demyelination after treatment with nivolumab for melanoma. Cancer Immunol Res. 2015 Dec;3(12):1299–1302.
   PubMed Web of Science ®Google Scholar
• Cao Y, Nylander A, Ramanan S, et al. CNS demyelination and enhanced myelin-reactive responses after ipilimumab treatment. Neurology. 2016 Apr 19;86(16):1553–1556.
   PubMed Web of Science ®Google Scholar
• Kolb NA, Trevino CR, Waheed W, et al. Neuromuscular complications of immune checkpoint inhibitor therapy. Muscle Nerve. 2018 Jan 17;58(1):10–22.
   Web of Science ®Google Scholar
• Psimaras D, Velasco R, Birzu C, et al. Immune checkpoint inhibitors-induced neuromuscular toxicity: from pathogenesis to treatment. J Peripher Nerv Syst. 2019 Oct;24(Suppl 2):S74–s85.
   PubMedGoogle Scholar
• Safa H, Johnson DH, Trinh VA, et al. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer. 2019 Nov 21;7(1):319.
   PubMed Web of Science ®Google Scholar
• Psimaras D. Neuromuscular complications of immune checkpoint inhibitors. Presse Med. 2018 Nov–Dec;47(11–12 Pt 2):e253–e59.
   PubMed Web of Science ®Google Scholar
• Suzuki S, Ishikawa N, Konoeda F, et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology. 2017 Sep 12;89(11):1127–1134.
   PubMed Web of Science ®Google Scholar
• Grob D, Brunner N, Namba T, et al. Lifetime course of myasthenia gravis. Muscle Nerve. 2008 Feb;37(2):141–149.
   PubMed Web of Science ®Google Scholar
• Wendell LC, Levine JM. Myasthenic crisis. Neurohospitalist. 2011 Jan;1(1):16–22.
   PubMedGoogle Scholar
• Liewluck T, Kao JC, Mauermann ML. PD-1 Inhibitor-associated myopathies: emerging immune-mediated myopathies. J Immunother. 2018 May;41(4):208–211.
   PubMed Web of Science ®Google Scholar
• Touat M, Maisonobe T, Knauss S, et al. Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. Neurology. 2018 Sep 4;91(10):e985–e94.
   PubMed Web of Science ®Google Scholar
• Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016 Nov 3;375(18):1749–1755.
   PubMed Web of Science ®Google Scholar
• Moslehi JJ, Salem JE, Sosman JA, et al. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018 Mar 10;391(10124):933.
   PubMed Web of Science ®Google Scholar
• Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018 Dec 1;4(12):1721–1728.
   PubMed Web of Science ®Google Scholar
• Bonaca MP, Olenchock BA, Salem JE, et al. Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology. Circulation. 2019 Jul 2;140(2):80–91.
   PubMedGoogle Scholar
• Gilhus NE. Myasthenia Gravis. New England J Med. 2016 Dec 29;375(26):2570–2581.
   PubMed Web of Science ®Google Scholar
• Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016 Jul 26;87(4):419–425.
   PubMed Web of Science ®Google Scholar
• Roper J, Fleming ME, Long B, et al. Myasthenia gravis and crisis: evaluation and management in the emergency department. J Emerg Med. 2017 Dec;53(6):843–853.
   PubMed Web of Science ®Google Scholar
• Maeda O, Yokota K, Atsuta N, et al. Nivolumab for the treatment of malignant melanoma in a patient with pre-existing myasthenia gravis. Nagoya J Med Sci. 2016 Feb;78(1):119–122.
   PubMed Web of Science ®Google Scholar
• Polat P, Donofrio PD. Myasthenia gravis induced by nivolumab therapy in a patient with non-small-cell lung cancer. Muscle Nerve. 2016 Sep;54(3):507.
   PubMed Web of Science ®Google Scholar
• Kimura T, Fukushima S, Miyashita A, et al. Myasthenic crisis and polymyositis induced by one dose of nivolumab. Cancer Sci. 2016 Jul;107(7):1055–1058.
   PubMed Web of Science ®Google Scholar
• Shirai T, Sano T, Kamijo F, et al. Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma. Jpn J Clin Oncol. 2016 Jan;46(1):86–88.
   PubMed Web of Science ®Google Scholar
• Somnier FE. Clinical implementation of anti-acetylcholine receptor antibodies. J Neurol Neurosurg Psychiatry. 1993 May;56(5):496–504.
   PubMed Web of Science ®Google Scholar
• Suzuki S, Utsugisawa K, Yoshikawa H, et al. Autoimmune targets of heart and skeletal muscles in myasthenia gravis. Arch Neurol. 2009 Nov;66(11):1334–1338.
   PubMedGoogle Scholar
• Koneczny I, Herbst R. Myasthenia gravis: pathogenic effects of autoantibodies on neuromuscular architecture. Cells. 2019 Jul 2;8(7):671.
   PubMed Web of Science ®Google Scholar
• Romi F, Suzuki S, Suzuki N, et al. Anti-voltage-gated potassium channel Kv1.4 antibodies in myasthenia gravis. J Neurol. 2012 Jul;259(7):1312–1316.
   PubMed Web of Science ®Google Scholar
• Dubey D, David WS, Amato AA, et al. Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies. Neurology. 2019 Sep 10;93(11):e1093–e103..
   PubMed Web of Science ®Google Scholar
• Pan PC, Haggiagi A. Neurologic immune-related adverse events associated with immune checkpoint inhibition. Curr Oncol Rep. 2019 Nov 27;21(12):108.
   PubMed Web of Science ®Google Scholar
• McNeill CJ, Fehmi J, Gladwin J, et al. A rare case of miller fisher variant of guillain-barré syndrome (GBS) induced by a checkpoint inhibitor. BMJ Case Rep. 2019 Aug 13;12(8):e229443.
   PubMedGoogle Scholar
• Tanaka R, Maruyama H, Tomidokoro Y, et al. Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset guillain-barre syndrome: a case report. Jpn J Clin Oncol. 2016 Sep;46(9):875–878.
   PubMed Web of Science ®Google Scholar
• Rajabally YA, Attarian S. Chronic inflammatory demyelinating polyneuropathy and malignancy: a systematic review. Muscle Nerve. 2018 Jun;57(6):875–883.
   PubMed Web of Science ®Google Scholar
• Van raamsdonk CD, Deo M. Links between schwann cells and melanocytes in development and disease. Pigment Cell Melanoma Res. 2013 Sep;26(5):634–645.
   PubMed Web of Science ®Google Scholar
• Schneiderbauer R, Schneiderbauer M, Wick W, et al. PD-1 Antibody-induced guillain-barre syndrome in a patient with metastatic melanoma. Acta Derm Venereol. 2017 Mar 10;97(3):395–396.
   PubMed Web of Science ®Google Scholar
• Compter A, Boogerd W, van thienen JV, et al. Acute polyneuropathy in a metastatic melanoma patient treated with vemurafenib and cobimetinib. Neurol Clin Pract. 2017 Oct;7(5):418–420.
   PubMedGoogle Scholar
• Devic P, Amini-adle M, Camdessanche JP, et al. Demyelinating polyradiculoneuropathy under combined BRAF/MEK inhibitors. Eur J Cancer. 2017 Jun;78:103–104.
   PubMed Web of Science ®Google Scholar
• Johnson DB, Wallender EK, Cohen DN, et al. Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy. Cancer Immunol Res. 2013 Dec;1(6):373–377.
   PubMed Web of Science ®Google Scholar
• Frederick DT, Piris A, Cogdill AP, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013 Mar 1;19(5):1225–1231.
   PubMed Web of Science ®Google Scholar
• Ebert PJR, Cheung J, Yang Y, et al. MAP Kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade. Immunity. 2016 Mar 15;44(3):609–621.
   PubMed Web of Science ®Google Scholar
• Hu-Lieskovan S, Mok S, Homet moreno B, et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med. 2015 Mar 18;7(279):279ra41.
   PubMed Web of Science ®Google Scholar
• Oaklander AL, Lunn MP, Hughes RA, et al. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. Cochrane Database Syst Rev. 2017 Jan;13(1):Cd010369.
   Google Scholar
• Chen X, Haggiagi A, Tzatha E, et al. Electrophysiological findings in immune checkpoint inhibitor-related peripheral neuropathy. Clin Neurophysiol. 2019 Aug;130(8):1440–1445.
   PubMed Web of Science ®Google Scholar
• Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018 Nov 29;379(22):2108–2121.
   PubMed Web of Science ®Google Scholar
• Kelly wu W, Broman KK, Brownie ER, et al. Ipilimumab-induced guillain-barre syndrome presenting as dysautonomia: an unusual presentation of a rare complication of immunotherapy. J Immunother. 2017 Jun;40(5):196–199.
   PubMed Web of Science ®Google Scholar